BioSpace News Archive

Fresenius Kabi announced that its Ivenix® Infusion System has been selected by the Metrodora Institute to meet the Institute’s infusion medicine needs.

Harbour BioMed announces that the National Medical Products Administration (NMPA) of China has accepted the Biologics License Application (BLA) of batoclimab (HBM9161) for the treatment of generalized myasthenia gravis (gMG).

Astellas Pharma Inc. and Mitsui Fudosan Co., Ltd. announced that Astellas will establish a “TME imaging and interactive research for innovation " open innovation hub in October, 2023 in “MITSUI LINK-Lab KASHIWA-NO-HA 1" operated by Mitsui Fudosan.

Shanghai Junshi Biosciences Co., Ltd announced that the U.S. FDA has recently agreed a randomized, double-blind, placebo-controlled, multi-regional phase 3 clinical study of tifcemalimab, an anti-BTLA monoclonal antibody used in combination with toripalimab, an anti-PD-1 monoclonal antibody, as consolidation therapy for patients with limited-stage small cell lung cancer without disease progression following chemoradiotherapy may proceed.

Curasight A/S announces positive results from the investigator-initiated phase II study using uPAR-PET in primary brain cancer.

NanoViricides, Inc. reports that clinical trials of its broad-spectrum antiviral drug NV-CoV-2 began on June 17, 2023 with two oral drug products: NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies.

Devyser is thrilled to announce the launch of two new products, Devyser LynchFAP and Devyser BRCA PALB2.

ZAP Surgical Systems, Inc., a leading innovator in the field of surgical robotics, announced that the company received National Medical Products Administration approval in China for its ZAP-X® Gyroscopic Radiosurgery® platform.

Ribbon Biolabs, the DNA synthesis company, announced the appointment of Roopom Banerjee as Executive Chairman of its Board of Directors.

BioMed X, a German independent research institute, announces the start of its first research project in collaboration with Sanofi: “Next Generation Virtual Patient Engine for Clinical Translation of Drug Candidates”.